The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -14,909,754 |
| Depreciation and amortization | 504,836 |
| Stock-based compensation expense | 671,474 |
| Fair value adjustment on warrants | 3,810,278 |
| Accounts and other receivables | -597,242 |
| Inventory | 25,940 |
| Prepaid expenses and other assets | 90,060 |
| Accounts payable | -225,410 |
| Accrued expenses | 319,267 |
| Unearned revenue | 18,001 |
| Operating lease right-of-use asset | -1,224 |
| Net cash used in operating activities | -9,328,842 |
| Purchase of property and equipment | 60,568 |
| Net cash used in investing activities | -60,568 |
| Proceeds from issuance of common stock from direct offering | 11,071,534 |
| Proceeds from exercise of warrants | 4,814,027 |
| Proceeds from issuance of convertible preferred stock | 990,000 |
| Payment of offering costs for financing activities | 1,771,939 |
| (payments) proceeds from loans payable | -45,375 |
| Principal repayments on finance leases | 324,346 |
| Net cash provided by financing activities | 14,733,901 |
| Net change in cash and cash equivalents | 5,344,491 |
| Cash and cash equivalents at beginning of year | 1,105,291 |
| Cash and cash equivalents at end of year | 6,449,782 |
bioAffinity Technologies, Inc. (BIAFW)
bioAffinity Technologies, Inc. (BIAFW)